Compare Vanguard Short Term Corporate Bond ETF (VCSH) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Short Term Corporate Bond ETF vs Zimmer Biomet Holdings Inc — how do they compare? Vanguard Short Term Corporate Bond ETF trades at $77.28 (market cap $51.90B), while Zimmer Biomet Holdings Inc trades at $88.74 (market cap $16.95B). The key difference: Vanguard Short Term Corporate Bond ETF is far larger — about 3.1× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Vanguard Short Term Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Short Term Corporate Bond ETF for 52 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| VCSH | ZBH | |
|---|---|---|
Market Cap | $51.90B | $16.95B |
Volume | 2,892,221 | 2,505,240 |
Sector | Fixed Income | Health |
52-Week High | $80.20 | $103.98 |
52-Week Low | $77.03 | $79.58 |
Typical Hold Time | 52 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VCSH trades at $77.285 with minimal daily movement (+0.02%). The technical outlook is bearish with moving averages signaling caution, though oscillators remain neutral. Recent news highlights VCSH's competitive 4.5% dividend yield and low 0.03% expense ratio, positioning it as a stable income alternative to CDs or stable value funds. The fund's short 2.7-year duration minimizes interest rate risk, but credit spreads remain tight, limiting near-term upside potential.
VCSH offers conservative investors higher yields than traditional safe-harbor investments with minimal volatility. The primary risk involves corporate credit exposure during economic downturns, while the main opportunity lies in its attractive risk-adjusted returns for short-term bond allocations. Current market sentiment is neutral with some institutional rotation observed in recent filings.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
